Walleye Capital LLC
Institutional investor · Portfolio as of Q3 2019
Top Holdings1,849 positions
AbbVie Inc | 245,700 | $18.6M | 1.1% | — | — | — | Increased — |
Amgen Inc | 92,900 | $18M | 1.1% | — | — | — | Increased — |
Vertex Pharmaceuticals Inc | 88,600 | $15M | 0.9% | — | — | — | Increased — |
Palo Alto Networks Inc | 67,200 | $13.7M | 0.8% | — | — | — | Increased — |
Eli Lilly & Co | 116,900 | $13.1M | 0.8% | — | — | — | Increased — |
Quintiles IMS Holdings Inc | 85,400 | $12.8M | 0.8% | — | — | — | Increased — |
Zoetis Inc | 100,200 | $12.5M | 0.7% | — | — | — | Increased — |
Johnson & Johnson | 86,900 | $11.2M | 0.7% | — | — | — | Increased — |
Thermo Fisher Scientific Inc | 38,200 | $11.1M | 0.7% | — | — | — | Increased — |
Southern Co/The | 179,500 | $11.1M | 0.7% | — | — | — | Increased — |
Jazz Pharmaceuticals PLC | 84,000 | $10.8M | 0.6% | — | — | — | Increased — |
Merck & Co Inc | 125,700 | $10.6M | 0.6% | — | — | — | Increased — |
Archer-Daniels-Midland Co | 239,600 | $9.8M | 0.6% | — | — | — | Increased — |
Regeneron Pharmaceuticals Inc | 35,400 | $9.8M | 0.6% | — | — | — | Increased — |
Lowe's Cos Inc | 89,300 | $9.8M | 0.6% | — | — | — | Increased — |
Gilead Sciences Inc | 151,700 | $9.6M | 0.6% | — | — | — | Increased — |
Agilent Technologies Inc | 117,700 | $9M | 0.5% | — | — | — | Increased — |
CVS Health Corp | 137,000 | $8.6M | 0.5% | — | — | — | Increased — |
Bristol-Myers Squibb Co | 166,500 | $8.4M | 0.5% | — | — | — | Increased — |
Target Corp | 75,400 | $8.1M | 0.5% | — | — | — | Increased — |
Walleye Capital LLC manages $1.7B across 1849 positions as of Q3 2019. Top holdings: ABBV calls (1.1%), AMGN calls (1.1%), VRTX calls (0.9%). Fund DNA: Diversified Scout. HoldingsIntel Score: 2.5/5.0.
Active quarter - 230 new positions, 230 exits, 123 increased. No standout high-conviction moves this quarter. Portfolio: $1.7B across 1849 positions.
Top holdings by portfolio weight
Portfolio allocation by GICS sector
Behavioral investing profile
Position Outcomes
Best and worst performing positions by estimated return
Top Winners
Top Losers
Cost basis estimates based on full filing history using quarter-end prices. Actual transaction prices are not disclosed in 13F filings.
Similar Funds
Funds with similar investing DNA
Explore More
Accumulation Streaks
Positions with 2+ consecutive quarters of increases - persistent directional conviction.
Continue exploring
Data sourced from SEC EDGAR 13F filings. Not financial advice. Full disclaimer
Verify source filings on SEC EDGAR